+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06350097

First-line Treatment Study of Osimertinib With or Without Datopotamab Deruxtecan for EGFR Mutation-positive Advanced Non-small Cell Lung Cancer

Led by AstraZeneca · Updated on 2026-08-26

582

Participants Needed

167

Research Sites

179 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of osimertinib tablets combined with Datopotamab Deruxtecan intravenous infusion compared to osimertinib alone as a first treatment for participants with locally advanced or metastatic non-small cell lung cancer NSCLC that has specific EGFR mutations Ex19del andor L858R. This global Phase III, open-label, randomized study includes participants who have not received prior therapy for advanced disease, aiming to assess treatment benefits over approximately 8 years. Participants are randomly assigned to one of two groups one group receives osimertinib 80 mg orally once daily plus Datopotamab Deruxtecan 6 mgkg by intravenous infusion every 3 weeks, while the other group receives osimertinib 80 mg orally once daily alone. Treatment continues until disease progression, unacceptable side effects, or other discontinuation reasons. Visits occur every 3 weeks during treatment, with additional assessments every 6 weeks from cycle 7 to cycle 17, then every 12 weeks for those on osimertinib alone or after discontinuing Datopotamab Deruxtecan. Participants will attend regular visits for treatment administration and assessments, including scans and laboratory tests to monitor disease status and safety. Researchers will measure progression-free survival, overall survival, response rates, and the impact on brain metastases over the study period. Pharmacokinetics and immunogenicity of the drugs will also be evaluated. The study includes continuous safety monitoring and may last up to 8 years, with visits and evaluations scheduled throughout treatment and follow-up.

CONDITIONS

Brief Title

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here